GBL cuts Concentrix stake below 5% after 6M sale

Groupe Bruxelles Lambert and affiliates have sharply reduced their stake in Concentrix Corporation.

Rhea-AI Filing Summary

Groupe Bruxelles Lambert and affiliates have sharply reduced their stake in Concentrix Corporation. Through subsidiaries including Sapiens S.à r.l., FINPAR V and FINPAR VI, they now beneficially own 2,773,667 shares of Common Stock, representing 4.55% of Concentrix’s 61,004,826 outstanding shares as of March 31, 2026.

The change follows Sapiens’ April 29, 2026 block trade of 6,000,000 shares at $22.25 per share under Rule 144, which brought the group’s holdings below the 5% reporting threshold, ending their ongoing Schedule 13D reporting obligations. They may also receive up to 442,759 contingent Earnout Shares if share-price conditions set in a prior agreement are met.

Insights

Equity ownership analyst

Large holder sold 6M Concentrix shares, falling below 5% ownership.

The filing shows the Groupe Bruxelles Lambert group now holds 2,773,667 Concentrix shares, or 4.55% of the company, after a significant reduction from a prior larger position. This reflects a major secondary sale, not an issuance of new shares.

On April 29, 2026, Sapiens executed a Rule 144 block trade of 6,000,000 shares at $22.25 per share. Because their ownership dropped below 5%, the group states it no longer has ongoing beneficial-ownership reporting obligations. Future company filings may give more color on any related governance or relationship changes.

Key Figures

Current beneficial ownership: 2,773,667 shares (4.55%) Shares outstanding: 61,004,826 shares Block trade size: 6,000,000 shares +5 more

8 metrics

Current beneficial ownership 2,773,667 shares (4.55%) Concentrix common stock held by GBL group after transactions

Shares outstanding 61,004,826 shares Concentrix common stock outstanding as of March 31, 2026

Block trade size 6,000,000 shares Concentrix shares sold by Sapiens on April 29, 2026

Block trade price $22.25 per share Price for the April 29, 2026 Rule 144 block trade

Earnout Shares 442,759 shares Potential additional Concentrix shares if share-price conditions are met

Sapiens post-trade holding 2,699,080 shares Concentrix shares directly held by Sapiens S.à r.l.

FINPAR VI holding 38,623 shares Concentrix shares directly held by FINPAR VI

FINPAR V holding 35,964 shares Concentrix shares directly held by FINPAR V

Key Terms

Schedule 13D, Rule 144, beneficially own, Earnout Shares, +2 more

6 terms

Schedule 13D regulatory

"This Amendment No. 2 amends and supplements the , originally filed on October 5, 2023"

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

Rule 144 regulatory

"Sapiens sold 6,000,000 shares of Common Stock for $22.25 per share, in a block trade pursuant to Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

beneficially own financial

"The Reporting Persons beneficially own an aggregate of 2,773,667 shares of Common Stock, representing 4.55% of the outstanding shares"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

Earnout Shares financial

"The Reporting Persons are also entitled to receive an additional 442,759 Earnout Shares if certain conditions set forth in the SPA occur"

Earnout shares are company stock promised to sellers as part of an acquisition that only becomes payable if the acquired business hits agreed future performance targets, like revenue or profit goals. They matter to investors because they can increase the number of shares outstanding (dilution), tie seller incentives to future success, and create uncertainty about the actual cost of the deal and future ownership unless the performance conditions are clearly understood.

volume weighted average prices financial

"including the share price of Common Stock reaching $170.00 per share within seven years from the Closing Date (based on daily volume weighted average prices measured over a specified period)"

Put Option Share Purchase and Contribution Agreements financial

"See "Put Option Share Purchase and Contribution Agreements" in Item 3 of the Original"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much of Concentrix (CNXC) does Groupe Bruxelles Lambert now own?

Groupe Bruxelles Lambert and its affiliates now beneficially own 2,773,667 Concentrix common shares, equal to 4.55% of outstanding stock. This percentage is based on 61,004,826 shares outstanding as of March 31, 2026, reported in Concentrix’s Form 10-Q for the quarter ended February 28, 2026.

What major share sale in Concentrix (CNXC) is disclosed in this Schedule 13D/A?

The filing reports that Sapiens S.à r.l., an affiliate of Groupe Bruxelles Lambert, sold 6,000,000 Concentrix common shares on April 29, 2026. The shares were sold in a block trade under Rule 144 at a price of $22.25 per share, significantly reducing the group’s holdings.

Why did Groupe Bruxelles Lambert file Amendment No. 2 to its Concentrix (CNXC) Schedule 13D?

Amendment No. 2 updates ownership information after a large April 29, 2026 sale by Sapiens. Following the 6,000,000-share block trade, the reporting group’s beneficial ownership fell to 4.55% of Concentrix common stock, triggering an update to Items 5(a)–(c) and 5(e) of the prior Schedule 13D.

Does Groupe Bruxelles Lambert still have ongoing beneficial ownership reporting duties for Concentrix (CNXC)?

After the April 29, 2026 sale, the reporting persons state they ceased to beneficially own 5% or more of Concentrix common stock. As a result, they indicate they have no further beneficial ownership reporting obligations under Section 13(d) for this position, based on current holdings.

What potential additional Concentrix (CNXC) shares can the reporting group still receive?

The reporting persons may receive up to 442,759 additional Concentrix Earnout Shares if conditions in a prior share purchase agreement are met. These conditions include the Concentrix share price reaching $170.00 per share within seven years from the closing date, measured using daily volume weighted average prices.

How is beneficial ownership among the GBL entities in Concentrix (CNXC) structured?

As of this amendment, FINPAR VI directly holds 38,623 shares, FINPAR V holds 35,964 shares, and Sapiens holds 2,699,080 shares. GBL Verwaltung S.A. is the parent of Sapiens, and Groupe Bruxelles Lambert is parent of GBL Verwaltung, FINPAR VI and FINPAR V, so it may be deemed to own 2,773,667 shares in total.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/01/2026 - 04:15 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 2)

CONCENTRIX CORPORATION

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

20602D101

(CUSIP Number)

Priscilla Maters
c/o Groupe Bruxelles Lambert, 24 avenue Marnix
Brussels, C9, 1000
32 22891717

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

04/29/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 20602D101

1

Name of reporting person

FINPAR VI SA

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

BELGIUM

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 38,623.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 38,623.00

11

Aggregate amount beneficially owned by each reporting person

38,623.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.06 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP Number(s): 20602D101

1

Name of reporting person

FINPAR V SA

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

BELGIUM

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 35,964.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 35,964.00

11

Aggregate amount beneficially owned by each reporting person

35,964.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.06 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP Number(s): 20602D101

1

Name of reporting person

Sapiens S.ar.l.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

LUXEMBOURG

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 2,699,080.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 2,699,080.00

11

Aggregate amount beneficially owned by each reporting person

2,699,080.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.42 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP Number(s): 20602D101

1

Name of reporting person

GBL Verwaltung S.A.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

LUXEMBOURG

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 2,699,080.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 2,699,080.00

11

Aggregate amount beneficially owned by each reporting person

2,699,080.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.42 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP Number(s): 20602D101

1

Name of reporting person

Groupe Bruxelles Lambert

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

BELGIUM

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 2,773,667.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 2,773,667.00

11

Aggregate amount beneficially owned by each reporting person

2,773,667.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.55 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.0001 per share
(b)	Name of Issuer: CONCENTRIX CORPORATION
(c)	Address of Issuer's Principal Executive Offices: 39899 BALENTINE DRIVE, NEWARK, CALIFORNIA , 94560.
Item 1 Comment: This Amendment No. 2 (this "Amendment No. 2") amends and supplements the Schedule 13D, originally filed on October 5, 2023 (the "Original Schedule 13D") and Amendment No. 1, filed on January 30, 2026 ("Amendment No. 1" and, together with the Original Schedule 13D and this Amendment No. 2, the "Schedule 13D") relating to the common stock, par value $0.0001 per share (the "Common Stock"), of Concentrix Corporation (the "Issuer"), a Delaware corporation. Except as specifically provided herein, this Amendment No. 2 does not modify any of the information previously reported on the Schedule 13D. Capitalized terms not otherwise defined in this Amendment No. 2 shall have the same meanings ascribed thereto in the Schedule 13D.
Item 5.	Interest in Securities of the Issuer
(a)	Items 5(a) - (c) and Item 5(e) of Schedule 13D are hereby amended and restated as follows: The responses of the Reporting Persons to rows (11) and (13) on the cover pages hereto is incorporated by reference herein. The Reporting Persons beneficially own an aggregate of 2,773,667 shares of Common Stock, representing 4.55% of the outstanding shares of Common Stock of the Issuer. Calculations of the percentage of the shares of Common Stock beneficially owned are based on an aggregate of 61,004,826 shares of Common Stock outstanding as of March 31, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended February 28, 2026, filed with the SEC on April 3, 2026. As of the date hereof, (i) FINPAR VI directly holds 38,623 shares of Common Stock; (ii) FINPAR V directly holds 35,964 shares of Common Stock; and (iii) Sapiens directly holds 2,699,080 shares of Common Stock. GBLV is the parent company of Sapiens, and therefore may be deemed to beneficially own the 2,699,080 shares of Common Stock directly held by the foregoing. GBL is the parent company of GBLV, FINPAR VI and FINPAR V and therefore may be deemed to beneficially own the 2,773,667 shares of Common Stock directly held by Sapiens, FINPAR VI and FINPAR V The Reporting Persons are also entitled to receive an additional 442,759 Earnout Shares if certain conditions set forth in the SPA occur, including the share price of Common Stock reaching $170.00 per share within seven years from the Closing Date (based on daily volume weighted average prices measured over a specified period). See "Put Option Share Purchase and Contribution Agreements" in Item 3 of the Original Schedule 13D. Neither the filing of this Schedule 13D nor any of its contents shall be deemed to constitute an admission that any Reporting Person is the beneficial owner of the Common Stock referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
(b)	The responses of the Reporting Persons to rows (7) through (10) on the cover pages hereto and Item 5(a) hereof are incorporated by reference herein.
(c)	On April 29, 2026, Sapiens sold 6,000,000 shares of Common Stock for $22.25 per share, in a block trade pursuant to Rule 144. Except for such transaction, the Reporting Persons have not effected any other transactions in Common Stock since the filing of Amendment No. 1.
(e)	After giving effect to the April 29, 2026 sale by Sapiens, the Reporting Persons ceased to beneficially own 5% of the Common Stock and have no further beneficial ownership reporting obligations.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

FINPAR VI SA

Signature:	/s/ Priscilla Maters - /s/ Xavier Likin
Name/Title:	Priscilla Maters / Director - Xavier Likin / Director
Date:	05/01/2026

FINPAR V SA

Signature:	/s/ Priscilla Maters - /s/ Xavier Likin
Name/Title:	Priscilla Maters / Director - Xavier Likin / Director
Date:	05/01/2026

Sapiens S.ar.l.

Signature:	/s/ Priscilla Maters - /s/ Serge Saussoy
Name/Title:	Priscilla Maters / Director - Serge Saussoy / Director
Date:	05/01/2026

GBL Verwaltung S.A.

Signature:	/s/ Priscilla Maters - /s/ Serge Saussoy
Name/Title:	Priscilla Maters / Director - Serge Saussoy / Director
Date:	05/01/2026

Groupe Bruxelles Lambert

Signature:	/s/ Priscilla Maters - /s/ Xavier Likin
Name/Title:	Priscilla Maters / General Counsel - Xavier Likin / Chief Financial Officer
Date:	05/01/2026